Regeneron Pharmaceuticals Inc (REGN.OQ)
15 Aug 2018
Mon, Aug 6 2018
Regeneron Pharmaceuticals Inc said on Monday it will invest $100 million in cancer drug developer bluebird bio Inc, and the companies will jointly develop new cell therapies for cancer.
Regeneron Pharmaceuticals Inc reported a better-than-expected quarterly profit on Thursday, helped by higher sales of its newer medicines and outlined a growth strategy for its flagship drug Eylea, which is facing heightened competition.
Aug 2 Drugmaker Regeneron Pharmaceuticals Inc reported a better-than-expected quarterly profit, helped by higher sales of eczema drug Dupixent.
Regeneron Pharmaceuticals Inc disappointed Wall Street with lower-than-expected sales of its newer treatments, eczema medicine Dupixent and heart drug Praluent, exacerbating concerns over the company's future sales growth as its best-selling eye drug Eylea faces more competition.
* Shares down 2 pct (Adds background, comments from conf. call and analyst, updates shares)
* REGENERON REPORTS FIRST QUARTER 2018 FINANCIAL AND OPERATING RESULTS
May 3 Regeneron Pharmaceuticals Inc on Thursday posted a 92 percent rise in quarterly profit, as demand for its flagship eye treatment Eylea and eczema drug Dupixent increased.
Regeneron Pharmaceuticals Inc and Sanofi SA will slash the price of their expensive cholesterol drug for Express Scripts Holdings Co customers in exchange for greater patient access, with some savings to be shared with consumers, the companies said on Tuesday.
* REGENERON AND SANOFI TO LOWER NET PRICE OF PRALUENT® (ALIROCUMAB) INJECTION IN EXCHANGE FOR STRAIGHTFORWARD, MORE AFFORDABLE PATIENT ACCESS FOR EXPRESS SCRIPTS PATIENTS
May 1 Sanofi and Regeneron Pharmaceuticals said on Tuesday they had agreed to cut the price of their potent cholesterol drug, Praluent, under a deal with Express Scripts, the largest U.S. manager of prescription benefits.
- Regeneron: A Buy On Dupixent And Pipeline
- Your Daily Pharma Scoop: Redhill Receives NoA, Regeneron Gets CRL, Stemline NDA Under Review
- Regeneron's Pain Is Novartis' Gain
- Zoetis: Stock To Outperform On Long-Term Focus On Growth
- Biopharma 2018: Growth At A Reasonable Cost (GARC)
- Regeneron: How This Bull Can Continue To Gore The Bears